B

BioXcel Therapeutics
D

BTAI

0.50520
USD
-0.06
(-10.77%)
Market Closed
Volume
56,854
EPS
-2
Div Yield
-
P/E
-0
Market Cap
21,596,473
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    More
News

Title: BioXcel Therapeutics

Sector: Healthcare
Industry: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.